0001564590-21-040850.txt : 20210804 0001564590-21-040850.hdr.sgml : 20210804 20210804162525 ACCESSION NUMBER: 0001564590-21-040850 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210804 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210804 DATE AS OF CHANGE: 20210804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABIOMED INC CENTRAL INDEX KEY: 0000815094 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042743260 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-09585 FILM NUMBER: 211144378 BUSINESS ADDRESS: STREET 1: 22 CHERRY HILL DR CITY: DANVERS STATE: MA ZIP: 01923 BUSINESS PHONE: 9787775410 MAIL ADDRESS: STREET 1: 22 CHERRY HILL DRIVE CITY: DANVERS STATE: MA ZIP: 01923 8-K 1 abmd-8k_20210804.htm 8-K abmd-8k_20210804.htm
false 0000815094 0000815094 2021-08-04 2021-08-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2021

 

ABIOMED, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-09585

04-2743260

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

22 Cherry Hill Drive
Danvers, Massachusetts 01923

(Address of Principal Executive Offices, including Zip Code)

(978) 646-1400

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock, $0.01 par value

ABMD

The NASDAQ Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ 

 

 

 

 

Item 2.02   Results of Operations and Financial Condition.

 

On August 4, 2021, ABIOMED, Inc. (the “Company,” “we” or “us”) issued a press release reporting our financial results for our first quarter ended June 30, 2021. A copy of the press release is set forth as Exhibit 99.1 and is incorporated herein by reference. The information contained in this report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Act of 1934, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

 

Caution Concerning Forward-Looking Statements

This Form 8-K contains information that includes or is based on forward-looking statements within the meaning of the federal securities laws that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such statements include, but are not limited to, those regarding our financial performance and the impact of the COVID-19 pandemic on our operations and financial results and are subject to, among other risks, the COVID-19 pandemic and any related policies and actions by governments or other third parties. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Item 9.01   Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

  

Description

99.1

  

Press release dated August 4, 2021

 

 

Exhibit Index

 

Exhibit

  

Description

99.1

  

Press release dated August 4, 2021

 

 

 

104

 

Cover Page Interactive Data File (embedded with the Inline XBRL document)

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

ABIOMED, Inc.

 

 

 

 

 

 

 

 

By:

 

/s/ Todd A. Trapp

 

 

 

 

 

 

Todd A. Trapp

Vice President and Chief Financial Officer

(Authorized Signatory)

Date: August 4, 2021

 

 

 

 

 

 

 

 EX-99.1 2 abmd-ex991_6.htm EX-99.1 abmd-ex991_6.htm

Exhibit 99.1

 

 

ABIOMED ANNOUNCES RECORD REVENUE OF $253 MILLION, UP 53% YEAR OVER YEAR

 

­

Full year global revenue guidance increased for fiscal year 2022 to 22% - 24% growth versus prior year

 

 

DANVERS, Mass. — August 4, 2021 – Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended June 30, 2021.

 

Q1 financial summary and operational highlights:

 

•

Total revenue for the quarter totaled $252.6 million, an increase of 53% compared to $164.9 million during the same period of the prior fiscal year, driven by record global patient utilization with COVID recovery.

 

•

Worldwide Impella® heart pump product revenue for the quarter totaled $241.5 million, an increase of 55% compared to $155.4 million during the same period of the prior fiscal year.

 

•

U.S. Impella product revenue for the quarter totaled $197.5 million, an increase of 56% compared to $126.2 million during the same period of the prior fiscal year, with U.S. patient usage of Impella heart pumps up 43%.

 

•

Outside the U.S., Impella product revenue for the quarter totaled $44.0 million, an increase of 51% compared to $29.2 million during the same period of the prior fiscal year. Specifically, Japan product revenue for the quarter totaled $10.9 million, an increase of 24% compared to $8.8 million during the same period of the prior fiscal year, driven by a 78% increase in patient usage.

 

•

Gross margin for the quarter was 82.1% compared to 78.2% during the same period of the prior fiscal year.

 

•

The company announced the acquisition of the remaining interest of preCARDIA for $82.8 million. preCARDIA is the developer of a proprietary catheter and controller that will complement Abiomed’s product portfolio to expand options for upstream heart failure patients acutely decompensating. Annually, more than one million patients are admitted to hospitals in the United States with acute decompensated heart failure (ADHF)1. Despite available pharmaceutical treatments, heart failure is the leading cause of hospitalization in patients older than 65 years of age2. preCARDIA will provide heart failure specialists a minimally invasive solution with the potential to improve patient outcomes and lower the cost of care by providing early intervention with this new technology.

 

•

Non-GAAP income from operations* increased 94% to $66.2 million, or 26.2% non-GAAP operating margin* for the quarter, compared to $34.1 million non-GAAP income from operations, or 20.7% GAAP operating margin during the same period of the prior fiscal year. GAAP loss from operations for the quarter was $49.3 million, or (19.5%) GAAP operating margin primarily due to the accounting for the preCARDIA acquisition.

 

•

Non-GAAP net income* increased 95% to $51.1 million, or $1.10 per diluted share, compared to non-GAAP net income of $26.1, or $0.58 per diluted share during the same period of the prior fiscal year. GAAP net loss for the quarter was $26.5 million, or $(0.59) per diluted share compared to GAAP net income of $44.6 million, or $0.98 per diluted share during the same period of the prior fiscal year primarily due to the accounting for the preCARDIA acquisition.

 

1 

Ponikowski, et al., ESC Heart Fail. 2014 Sep;1(1):4-25.

2 

Olofsson, et al., Journal of Clinical Gerontology and Geriatrics, Volume 7, Issue 2, 2016, Pages 53-59

 

 

•

The company generated operating cash flows of $55.4 million during the quarter. As of June 30, 2021, the company had $804.8 million of cash and cash equivalents and marketable securities and no debt.

 

•

On June 29, the company announced Impella RP with SmartAssist received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) as safe and effective to treat acute right heart failure for up to 14 days. Impella RP with SmartAssist is the first single-access temporary percutaneous ventricular support device with sensor technology. The FDA issued an emergency use authorization (EUA) for Impella RP in June 2020 to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE). Since the onset of the COVID-19 pandemic, Impella RP has become a therapeutic choice for clinicians treating certain COVID-19 patients suffering right heart failure.

 

•

On August 2, the Centers for Medicare and Medicaid Services (CMS) released final Medicare payment levels for inpatient hospital discharges for fiscal year 2022 which takes effect October 1, 2021. Consistent with the April 2021 proposal and the Form 8-K filed with the SEC, CMS will reassign select ICD-10-PCS codes from MS-DRG 215 to additional cardiovascular related MS-DRGs to align clinical populations and better reflect hospital resources. We are pleased and supported the final rule coding changes to provide stability for multiple DRG payments. The Final Rule for the Inpatient Prospective Payment System (IPPS) is available on the CMS website.

 

“Q1 was a solid start with record global revenue and patient utilization in US, Europe and Japan, and we believe we are well-positioned for success in FY22,” said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer. “We will continue to create and deliver value by successfully advancing our innovation, clinical research and commercial distribution. We remain steadfast to creating the field of heart recovery and driving a new standard of care for circulatory support.”  

 

FISCAL YEAR 2022 OUTLOOK

 

The company is increasing fiscal year 2022 global revenue and now expects it to be in the range of $1,030 million to $1,050 million, representing 22% to 24% growth compared to fiscal year 2021, an increase from our original guidance of $990 million to $1,030 million, or 17% to 22% growth compared to fiscal year 2021. The company expects its fiscal year 2022 non-GAAP operating margin* to be in the range of 24% to 26%.

 

*ABOUT NON-GAAP FINANCIAL MEASURES 

 

To supplement its condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the company uses non-GAAP financial measures as described below. The company uses these non-GAAP financial measures for financial and operational decision-making and to evaluate period-to-period comparisons. The company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance and liquidity. The company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting, and analyzing future periods. The company believes these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by institutional investors and the analyst community to help them analyze the performance of the company’s business.

 

The company uses the following non-GAAP financial measures:

 

Non-GAAP (loss) income from operations: The company defines non-GAAP (loss) income from operations as (loss) income from operations, excluding the charge for the acquired in-process research and development related to the preCARDIA acquisition.

 

Non-GAAP operating margin: The company defines non-GAAP operating margin as operating margin, excluding the charge for the acquired in-process research and development related to the preCARDIA acquisition.

 

Non-GAAP net (loss) income and net (loss) income per diluted share: The company defines non-GAAP net (loss) income and net (loss) income per diluted share as net (loss) income and net (loss) income per diluted share, excluding the charge for the acquired in-process research and development related to the preCARDIA acquisition, the gain

recognized on its previously owned minority interest in preCARDIA, the unrealized gain on investment in Shockwave Medical and excess tax benefits associated with stock-based compensation. The company defines non-GAAP EPS as non-GAAP net (loss) income divided by non-GAAP diluted shares, which are calculated as GAAP weighted average outstanding shares plus dilutive potential shares outstanding during the period.

 

Refer to the “Reconciliation of GAAP to Non-GAAP Financial Measures” section of this press release.

 

The company reports non-GAAP financial measures in addition to, and not as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies. The company believes it is useful to exclude certain items because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods. The company believes that non-GAAP financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business.

 

EARNINGS CONFERENCE CALL DETAILS

 

The company will host a conference call to discuss the quarterly results at 8:00 a.m. ET on Thursday, August 5, 2021. The conference call will be hosted by Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd A. Trapp, Vice President and Chief Financial Officer.

To listen to the call live, please tune into the webcast via https://investors.abiomed.com/events-presentations or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11:00 a.m. ET August 5, 2021 through 11:00 a.m. ET on August 12, 2021. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 5929017.

 

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com. Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, Impella 5.5, Impella Connect, and SmartAssist are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries. Impella ECP, Impella XR Sheath, Impella BTR, CVAD, STEMI DTU, Automated Impella Controller and Abiomed Breethe OXY-1 System are pending trademarks of Abiomed, Inc.

 

FORWARD-LOOKING STATEMENTS

 

This release contains forward-looking statements, including, without limitation, statements regarding development of Abiomed's existing and new products, the company's progress toward commercial growth, future opportunities and expected regulatory approvals and statements in the paragraph under “Fiscal Year 2022 Outlook” section regarding certain business metrics on either or both a GAAP or non-GAAP basis. All statements, other than statements of historical facts, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. The company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including, without limitation: the scope, scale and duration of the impact of the COVID-19 pandemic, the company’s dependence on Impella® products for all of its revenues; the company’s ability to successfully compete against its existing or potential competitors; the acceptance of the company’s products by cardiac surgeons and interventional cardiologists; long sales and training cycles associated with expansion into new hospital cardiac centers; reduced market acceptance of the company’s products due to lengthy clinician training process; the company’s ability to effectively manage its growth; the company’s ability to successfully commercialize its products; the company’s ability to obtain regulatory approvals and market and sell its products in certain jurisdictions; enforcement actions and product liability suits relating to off-label uses of the company’s products; unsuccessful clinical trials or procedures relating to products under development; the company’s ability to maintain compliance with regulatory requirements; the failure of third-party payers to provide reimbursement of the company’s products; the company’s ability to increase manufacturing capacity to support continued demand for its products; the company or its vendors’ failure to achieve and maintain high manufacturing standards; the failure of the company’s suppliers to provide the components the company requires; the company’s ability to expand its direct sales activities into international markets; the outcome of ongoing securities class action litigation relating to our public disclosures, the company’s ability to integrate acquired companies into its operations and other risks and challenges detailed in the company's filings with the Securities and Exchange Commission (the “SEC”), including the most recently filed Annual Report on Form 10-K and the filings subsequently filed with or furnished to the SEC. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. Unless otherwise required by law, the company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

 

 

For further information please contact:  

 

Todd Trapp

Tom Langford

Vice President and Chief Financial Officer

Director, Corporate Communications & PR

978-646-1680

978-882-8408

ttrapp@abiomed.com

tlangford@abiomed.com

 

 

 

 

 

 

Abiomed, Inc. and Subsidiaries

 

Condensed Consolidated Balance Sheets

 

(Unaudited)

 

(in thousands, except share data)

 

 

 

 

 

 

 

 

 

 

 

 

June 30, 2021

 

 

March 31, 2021

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

175,454

 

 

$

232,710

 

Short-term marketable securities

 

 

347,577

 

 

 

350,985

 

Accounts receivable, net

 

 

88,645

 

 

 

97,179

 

Inventories

 

 

83,661

 

 

 

81,059

 

Prepaid expenses and other current assets

 

 

34,536

 

 

 

26,032

 

Total current assets

 

 

729,873

 

 

 

787,965

 

Long-term marketable securities

 

 

281,776

 

 

 

264,085

 

Property and equipment, net

 

 

198,234

 

 

 

197,129

 

Goodwill

 

 

79,006

 

 

 

78,568

 

Other intangibles, net

 

 

41,904

 

 

 

42,150

 

Deferred tax assets

 

 

4,958

 

 

 

11,380

 

Other assets

 

 

122,643

 

 

 

113,082

 

Total assets

 

$

1,458,394

 

 

$

1,494,359

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

29,807

 

 

$

34,842

 

Accrued expenses

 

 

56,462

 

 

 

66,046

 

Deferred revenues

 

 

24,094

 

 

 

24,322

 

Other current liabilities

 

 

2,760

 

 

 

3,759

 

Total current liabilities

 

 

113,123

 

 

 

128,969

 

Other long-term liabilities

 

 

11,314

 

 

 

10,162

 

Contingent consideration

 

 

25,577

 

 

 

24,706

 

Deferred tax liabilities

 

 

858

 

 

 

847

 

Total liabilities

 

 

150,872

 

 

 

164,684

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Class B Preferred Stock, $.01 par value

 

 

—

 

 

 

—

 

Authorized - 1,000,000 shares; Issued and outstanding - none

 

 

 

 

 

 

 

 

Common stock, $.01 par value

 

 

454

 

 

 

453

 

Authorized - 100,000,000 shares; Issued 48,070, 443 shares as of June 30, 2021 and 47,929,402 shares as of March 31, 2021

 

 

 

 

 

 

 

 

Outstanding 45,377,715 shares as of June 30, 2021 and 45,270,948 shares as of March 31, 2021

 

 

 

 

 

 

 

 

Additional paid in capital

 

 

815,416

 

 

 

800,690

 

Retained earnings

 

 

801,482

 

 

 

828,007

 

Treasury stock at cost 2,692,728 shares as of June 30, 2021 and 2,658,454 shares as of March 31, 2021

 

 

(297,619

)

 

 

(288,030

)

Accumulated other comprehensive loss

 

 

(12,211

)

 

 

(11,445

)

Total stockholders' equity

 

 

1,307,522

 

 

 

1,329,675

 

Total liabilities and stockholders' equity

 

$

1,458,394

 

 

$

1,494,359

 


 

Abiomed, Inc. and Subsidiaries

 

Condensed Consolidated Statements of Operations

 

(Unaudited)

 

(in thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended June 30,

 

 

 

2021

 

 

2020

 

Revenue

 

$

252,585

 

 

$

164,850

 

Costs and expenses:

 

 

 

 

 

 

 

 

Cost of revenue

 

 

45,188

 

 

 

35,983

 

Research and development

 

 

37,708

 

 

 

26,357

 

Selling, general and administrative

 

 

103,484

 

 

 

68,444

 

Acquired in-process research and development

 

 

115,490

 

 

 

—

 

 

 

 

301,870

 

 

 

130,784

 

(Loss) income from operations

 

 

(49,285

)

 

 

34,066

 

Other income:

 

 

 

 

 

 

 

 

Investment income, net

 

 

1,050

 

 

 

2,397

 

Other income, net

 

 

38,885

 

 

 

24,613

 

 

 

 

39,935

 

 

 

27,010

 

(Loss) income before income taxes

 

 

(9,350

)

 

 

61,076

 

Income tax provision

 

 

17,175

 

 

 

16,488

 

Net (loss) income

 

$

(26,525

)

 

$

44,588

 

 

 

 

 

 

 

 

 

 

Net (loss) income per share - basic

 

$

(0.59

)

 

$

0.99

 

Weighted average shares outstanding - basic

 

 

45,311

 

 

 

45,010

 

 

 

 

 

 

 

 

 

 

Net (loss) income per share - diluted

 

$

(0.59

)

 

$

0.98

 

Weighted average shares outstanding - diluted

 

 

45,311

 

 

 

45,549

 


 

Abiomed, Inc. and Subsidiaries

 

Reconciliation of GAAP to Non-GAAP Financial Measures

 

(Unaudited)

 

(in thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended June 30,

 

 

2021

 

 

2020

 

GAAP (loss) income from operations

$

(49,285

)

 

$

34,066

 

Acquired in-process research and development (1)

 

115,490

 

 

 

—

 

Non-GAAP income from operations

$

66,205

 

 

$

34,066

 

 

 

 

 

 

 

 

 

GAAP operating margin

 

(19.5

%)

 

 

20.7

%

Non-GAAP operating margin

 

26.2

%

 

 

20.7

%

 

 

 

 

 

 

 

 

GAAP net (loss) income

$

(26,525

)

 

$

44,588

 

Acquired in-process research and development (1)

 

115,490

 

 

 

—

 

Gain on previously held interest in preCARDIA (2)

 

(20,980

)

 

 

—

 

Excess tax benefits on stock-based compensation (3)

 

(3,630

)

 

 

(522

)

Gain on investment in Shockwave Medical (4)

 

(13,301

)

 

 

(17,934

)

Non-GAAP net income

$

51,054

 

 

$

26,132

 

 

 

 

 

 

 

 

 

GAAP diluted net (loss) income per share

$

(0.59

)

 

$

0.98

 

Acquired in-process research and development (1)

 

2.52

 

 

 

—

 

Gain on previously held interest in preCARDIA (2)

 

(0.46

)

 

 

—

 

Excess tax benefits on stock-based compensation (3)

 

(0.08

)

 

 

(0.01

)

Gain on investment in Shockwave Medical (4)

 

(0.29

)

 

 

(0.39

)

Non-GAAP diluted net income per share

$

1.10

 

 

$

0.58

 

 

 

 

 

 

 

 

 

GAAP diluted weighted-average shares outstanding

 

45,311

 

 

 

45,549

 

Non-GAAP diluted weighted-average shares outstanding

 

45,797

 

 

 

45,549

 

 

Notes:

 

(1) In May 2021, the company acquired the remaining interest in preCARDIA for $82.8 million. The company determined that substantially all of the fair value of the acquisition related to the acquired in-process research and development asset, which resulted in accounting for the transaction as an asset acquisition. The fair value of the acquired in-process research and development asset of $115.5 million is primarily comprised of the net consideration paid for the acquired remaining interest of $82.8 million and our previously owned minority interest in preCARDIA of $32.4 million. Since the acquired technology platform is pre-commercial and has not reached technical feasibility as defined by the accounting rules, the cost of the in-process research and development asset was expensed in the quarter, resulting in a charge of $115.5 million for the three months ended June 30, 2021.

 

(2) The company recognized a gain of $21.0 million related to its previously owned minority interest in preCARDIA as described in note (1), within the condensed consolidated statement of operations for the three months ended June 30, 2021.

 

(3) Amount represents the impact of excess tax benefits associated with stock-based compensation in each respective period presented. The company recognized excess tax benefits associated with stock-based compensation of $3.6 million and $0.5 million as an income tax benefit for the three months ended June 30, 2021 and 2020, respectively.

 

(4) Amount represents the unrealized gain on investment in Shockwave Medical in each respective period presented. The company recognized an unrealized gain on investment in Shockwave Medical of $17.7 million ($13.3 million, net of tax benefit) and $23.9 million ($17.9 million, net of tax benefit) within other income for the three months ended June 30, 2021 and 2020, respectively.

 

 

Refer to "About Non-GAAP Financial Measures" section of this press release.

 GRAPHIC 3 gwvntoey1qb1000001.jpg GRAPHIC begin 644 gwvntoey1qb1000001.jpg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end GRAPHIC 4 g3qexqguqkxs000001.jpg GRAPHIC begin 644 g3qexqguqkxs000001.jpg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end EX-101.SCH 5 abmd-20210804.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 6 abmd-20210804_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of each class Security12b Title Trading Symbol Trading Symbol Name of each exchange on which registered Security Exchange Name EX-101.PRE 7 abmd-20210804_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 abmd-8k_20210804_htm.xml IDEA: XBRL DOCUMENT 0000815094 2021-08-04 2021-08-04 false 0000815094 8-K 2021-08-04 ABIOMED, Inc. DE 001-09585 04-2743260 22 Cherry Hill Drive Danvers MA 01923 (978) 646-1400 Common Stock, $0.01 par value ABMD NASDAQ false false false false false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Aug. 04, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 04, 2021
Entity Registrant Name ABIOMED, Inc.
Entity Central Index Key 0000815094
Entity Emerging Growth Company false
Entity File Number 001-09585
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 04-2743260
Entity Address, Address Line One 22 Cherry Hill Drive
Entity Address, City or Town Danvers
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01923
City Area Code (978)
Local Phone Number 646-1400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class Common Stock, $0.01 par value
Trading Symbol ABMD
Name of each exchange on which registered NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports abmd-8k_20210804.htm abmd-20210804.xsd abmd-20210804_lab.xml abmd-20210804_pre.xml abmd-ex991_6.htm gwvntoey1qb1000001.jpg http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abmd-8k_20210804.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "abmd-8k_20210804.htm" ] }, "labelLink": { "local": [ "abmd-20210804_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "abmd-20210804_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "abmd-20210804.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "abmd", "nsuri": "http://www.abiomed.com/20210804", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "abmd-8k_20210804.htm", "contextRef": "C_0000815094_20210804_20210804", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "abmd-8k_20210804.htm", "contextRef": "C_0000815094_20210804_20210804", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.abiomed.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001564590-21-040850-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-040850-xbrl.zip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end